Is the anticonvulsant activity of levetiracetam dose-dependent?

• Conditions: G40.2; Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures

• Registration Number: DRKS00018874
• Lead Sponsor: Epilepsiezentrum Kork

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-10-09
• Study Completion: 2019-12-20
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 61

Inclusion Criteria

Inpatient treatment at Epilepsiezentrum Kork between 2009 and 2019
-Documented treatment with Levetiracetam
-Documented increasement of Levetiracetam dose while inpatient stay
-More than 1 seizure during the period prior to the dose increasement of LEV
-Sufficient inpatient stay period

Exclusion Criteria

-Non-epileptic seizures
-No treatment with levetiracetam or no dose increase of levetiracetam during inpatient stay
-Less than 1 seizure during the period prior to the dose increase of LEV
-Insufficient inpatient stay period
-Dose changes of the concomitant AED medication during the observation period
-Emergency medication required for seizures

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of seizure-free patients after LEV increase

Secondary Outcome Measures

Name	Time	Method
Percentage of patients with seizure reduction by at least 50% after LEV increase